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Abstract
Objectives MYC gene rearrangements in diffuse large B cell lymphomas (DLBCLs) result in high proliferation rates and are
associated with a poor prognosis. Strong proliferation is associated with high metabolic demand and tumour necrosis. The aim of
this study was to investigate differences in the presence of necrosis and semiquantitative 18F-FDG PETmetrics between DLBCL
cases with or without a MYC rearrangement. The prognostic impact of necrosis and semiquantitative 18F-FDG PET parameters
was investigated in an explorative survival analysis.
Methods Fluorescence in situ hybridisation analysis forMYC rearrangements, visual assesment, semiquantitative analysis of 18F-
FDG PET scans and patient survival analysis were performed in 61 DLBCL patients, treated at a single referral hospital between
2008 and 2015.
Results Of 61 tumours, 21 (34%) had a MYC rearrangement (MYC+). MYC status was neither associated with the presence of
necrosis on 18F-FDGPETscans (necrosisPET; p = 1.0) nor associatedwith the investigated semiquantitative parameters maximum
standard uptake value (SUVmax; p = 0.43), single highest SUVmax (p = 0.49), metabolic active tumour volume (MATV; p = 0.68)
or total lesion glycolysis (TLG; p = 0.62). A multivariate patient survival analysis of the entire cohort showed necrosisPET as an
independent prognostic marker for disease-specific survival (DSS) (HR = 13.9; 95% CI 3.0–65; p = 0.001).
Conclusions MYC rearrangements in DLBCL have no influence on the visual parameter necrosisPET or the semi-quantiative
parameters SUVmax, MATV and TLG. Irrespective of MYC rearrangements, necrosis
PET is an independent, adverse prognostic
factor for DSS.
Key Points
• Retrospective analysis indicates that MYC rearrangement is not associated with necrosis on 18F-FDG PET (necrosisPET) scans
or semiquantitative 18F-FDG PET parameters.
•NecrosisPET is a potential independent adverse prognostic factor for disease-specific survival in patients with DLBCL and is not
influenced by the presence of MYC rearrangements.
Keywords Diffuse, large B cell, lymphoma . MYC oncogene . Necrosis . Fluorodeoxyglucose F18 . Positron emission
tomography
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B-NHL B cell non-Hodgkin lymphoma
CT Computed tomography
DLBCL Diffuse large B cell lymphoma
DSS Disease-specific survival
FISH Fluorescence in situ hybridisation
LDH Lactate dehydrogenase
MATV Metabolically active tumour volume
(sum of all lesions within an
individual patient)
NCCN-IPI National Comprehensive Cancer
Network international prognostic
index
necrosisHist Necrosis as assessed by histological
scoring
necrosisPET Necrosis as assessed by
18F-FDG PET
OS Overall survival
PET Positron emission tomography
PFS Progression-free survival
SUV Standard uptake value
SUVmax Highest SUV per voxel within 1
lymphoma lesion (reported here as
the mean of SUVmax of all lesions
within an individual patient)
SUVmax single highest Highest SUVmax of all lesions
within an individual patient
TLG Total lesion glycolysis (sum
of all lesions within an
individual patient)
WHO World Health Organization.
Introduction
Diffuse large B cell lymphoma (DLBCL) accounts for 35% of
all B cell non-Hodgkin lymphomas (B-NHL) [1].
Approximately 10–15% of DLBCL cases harbour a MYC
gene rearrangement (MYC+), as assessed by fluorescence in
situ hybridisation (FISH) [2]. These lymphomas are
characterised by a very high proliferation rate. Patients bearing
a MYC+ lymphoma experience an aggressive clinical course
and have a poor prognosis when treated with the standard
regimen of rituximab, cyclophosphamide, doxorubicin, vin-
cristine and prednisolone (R-CHOP) [3]. In 2017, the World
Health Organization (WHO) established a new entity forMYC
rearranged DLBCL, called ‘high-grade B-cell lymphoma with
MYC and BCL2 and/or BCL6 rearrangements’ [1, 4].
MYC is an oncogenic transcription factor regulating a vast
array of cellular processes and pathways [5, 6]. Tumour cells
overexpressing MYC meet their high energy demands by in-
creased glucose uptake, glycolysis, lactate production and
amino acid consumption [7, 8]. However, unlike physiologi-
cal tissues, cancer cells frequently have acquired resistance to
apoptosis and cannot regulate their energy expenditure during
metabolic stress, resulting in cell death via necrosis when nu-
trient supply is compromised [9–11].
In B-NHL patients, 18F-fluorodeoxyglucose positron emis-
sion tomography (18F-FDG PET) scans are used for staging
and response assessment [12]. Tumour necrosis can be
assessed by visual inspection of 18F-FDG PET scans
(necrosisPET) [13]. Necrosis can be observed in 14–20% of
DLBCL cases and has been associated with an adverse prog-
nosis [14, 15]. Semiquantitative assessment of 18F-FDG PET
allows for relative comparison of parameters based on the
spatial distribution and degree of 18F-FDG uptake, and is cur-
rently being investigated as a tool for therapy monitoring and
assessing prognosis in B-NHL [16–18]. Still, data on the prog-
nostic value of the semiquantitative parameters maximum
standardised uptake value (SUVmax) and metabolically active
tumour volume (MATV) in DLBCL are conflicting [19–21].
MYC rearrangement, tumour necrosis (necrosisPET) and pa-
rameters derived from semiquantitative analysis of 18F-FDG
PET are fundamentally linked to metabolism, yet the relation-
ship between these factors remains unknown. We hypothesise
that the higher metabolic activity mediated byMYC rearrange-
ments might result in a higher incidence of necrosisPET and
increased semiquantitative parameters. The previously sug-
gested prognostic impact of necrosisPET [15] and semiquanti-
tative parameters [16–18] in DLBCL might be accredited to
their potential association with MYC rearrangements.
Therefore, the aim of this study was to investigate differ-
ences in the presence of necrosisPET and semiquantitative 18F-
FDG PET metrics between DLBCL cases with or without a
MYC rearrangement. The prognostic impact of these factors
was explored by means of survival analysis.
Materials and methods
Study design and case selection
For this retrospective single-centre study, consecutive patients
with newly diagnosed, histologically confirmed DLBCL be-
tween 2008 and 2015 were identified in the electronic
healthcare database of the University Medical Center
Groningen (UMCG), a reference centre for aggressive B cell
lymphomas. Cases of primary cutaneous DLBCL, primary cen-
tral nervous system lymphoma, primarymediastinal B cell lym-
phoma and immunodeficiency-associated lymphomas were ex-
cluded. The selection of cases for this study is summarised in
Fig. 1. Patients were stratified according to the National
Comprehensive Cancer Network international prognostic index
(NCCN-IPI) [22]. End of treatment response was assessed by
18F-FDG PET/CT scan. Tumour responses were classified
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according to Lugano criteria [12]. Follow-up was registered
until early October 2017. According to Dutch regulations, no
medical ethical committee approval was required for this retro-
spective, non-interventional study. Awaiver was obtained from
the medical ethics committee of the UMCG on November 13,
2018. The study utilised rest material from patients, the use of
which is regulated under the code for good clinical practice in
the Netherlands and does not require informed consent in ac-
cordance with Dutch regulations.
Pathology review
Pathology review was done using the 2008 WHO classifica-
tion of haematopoietic and lymphoid tissues (AD) [23].
Histological scoring for necrosis (necrosisHist) was done by
microscopic assessment of haematoxylin and eosin–stained
slides. Only microscopic areas with definite histopathological
signs of necrosis (i.e. karyolysis) were scored as positive for
necrosisHist.
MYC fluorescence in situ hybridisation
For evaluation of a MYC rearrangement, formalin-fixed par-
affin-embedded tissue blocks of primary tumour samples were
used. Interphase fluorescence in situ hybridisation (FISH) was
performed on 4-μm-thick whole tissue sections, using Vysis
break apart probes (Abbot Technologies) and standard FISH
protocols as previously described [24]. Researchers
performingMYC FISH analyses were blinded for results from
visual scoring, microscopic assessment of necrosis
(necrosisHist) and clinical outcome.
18F-FDG PET imaging
All 18F-FDG PET scans were performed prior to therapy.
Patients were allowed to continue all medication and fasted
for at least 6 h before whole-body (from the skull vertex to
mid-thigh level) three-dimensional PET images were ac-
quired. This was done 60 min after intravenous administration
of a standard dose of 3 MBq/kg (0.081 mCi/kg) bodyweight
18F-FDG on a BiographmCT (Siemens Healthineers), accord-
ing to the European Association of Nuclear Medicine
(EANM) procedure guidelines for tumour imaging with
FDG PET/CT (version 2.0) [25]. Acquisition was performed
in seven bed positions of 2-min emission scans for patients
60–90 kg. Patients with body weight less than 60 kg and more
than 90 kg body weight were scanned with 1 min and 3 min
per bed position, respectively. Low-dose transmission CTwas
used for attenuation correction. Low-dose CT and 18F-FDG
PET scans were automatically fused by the use of three-
dimensional fusion software (Siemens Healthineers) with
manual fine adjustments. Raw data were reconstructed
through ultra-high definition (Siemens Healthineers).
Computed tomography
Diagnostic CTs were acquired via integrated 18F-FDG PET/
CT scans according to the European Association of Nuclear
Medicine (EANM) procedure guidelines for tumour imaging
with FDG PET/CT (version 2.0) [25]. Bulky disease was de-
fined as any nodal lymphoma lesion > 10 cm in coronal, axial
or sagittal planes.
18F-FDG PET analysis
All 18F-FDG PET scans were visually assessed for the pres-
ence of tumour necrosis (necrosisPET) by an experienced read-
er (TCK), who was blinded to clinical, laboratory, biopsy and
follow-up findings, as previously described [15]. Areas within
any nodal or extranodal 18F-FDG PET–avid lymphomatous
lesions that showed no 18F-FDG uptake were registered as
having necrosisPET (Fig. 2); no specific visual scale was used.
Semiquantitative analysis was performed using an in-house
tool for quantitative 18F-FDG PET/CT analysis, as previously
described [26–28]. This programme automatically preselects
lesions using a SUVmax threshold of 4 and ametabolic volume
threshold of 2.5 ml. Unwanted preselected FDG-avid regions,
such as the bladder and brain, are removed by user interaction.
Finally, remaining FDG-avid segmentations are processed
Fig. 1 Flow-chart of case selection
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using a background-corrected 50% of SUV peak region grow-
ing method, as described by Frings et al [26], to obtain the
final tumour segmentations. In case obvious lymphoma
lesions were not selected (n = 3), they were manually added
after automatic tumour segmentation. From the final segmen-




Fig. 2 Visual assessment of necrosis and semiquantitative 18F-FDG PET
review process. a A 65-year-old man with diffuse large B cell lymphoma
(DLBCL) and tumour masses in the left dorsal chest wall and left pelvis,
as shown on the coronal maximum intensity projection (MIP) 18F-FDG
PET image (arrows). Coronal fused 18F-FDG PET/CT (b), axial CT (c)
and axial fused 18F-FDG PET/CT (d) show the tumour mass with
photopenic areas (arrow heads), in keeping with tumour necrosis.
Coronal and sagittal MIP 18F-FDG PET images (e and f) show tumour
segmentation (marked in red colour) for the calculation of metabolically
active tumour volume (MATV), total lesion glycolysis (TLG), maximum
standard uptake value (SUVmax), and single highest SUVmax
Table 1 Demographics and baseline disease characteristics of patients with diffuse large B cell lymphoma according to MYC status
MYC status
Total (n = 61) MYC− (n = 40) MYC+ (n = 21) p value
No. % No. % No. %
Gender
Male 36 59.0 24 60.0 12 57.1 1.0a
Female 25 41.0 16 40.0 9 42.9
Age
Median (range) 63 (26–91) 64 (26–91) 61 (30–79) 0.64b
Age ≤ 60 years 24 39.3 14 35.0 10 47.6 0.5a
Age > 60 years 37 60.7 26 65.0 11 52.4
Stage
I–II 22 36.0 15 37.5 7 33.3 0.97a
III–IV 39 63.9 25 62.5 14 66.7
NCCN-IPI score
0–3 30 49.2 22 55.0 8 38.1 0.32a
4–8 31 50.8 18 45.0 13 61.9
Serum LDH
Median (range) 282 (126–3037) 237 (126–1292) 381 (140–3037) 0.04b
Normal 29 47.5 22 55.0 7 33.3 0.18a
Elevated 32 52.5 18 45.0 14 66.7
Treatment
R-CHOP 56 91.8 37 92.5 19 90.5 0.36c
Intensive chemotherapy 3 4.9 1 2.5 2 9.5
Palliative 2 3.3 2 5.0 0 0
a Pearson’s chi-square test with Yates’ continuity correction
bWilcoxon rank-sum test with continuity correction
c Fisher’s exact test for count data
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total lesion glycolysis (TLG =MATV× SUVmean) and SUVs
are derived for each lesion independently as well as summed
over all lesions. Lesion selection and semiquantitative analy-
sis was performed by MH under direct supervision of an ex-
perienced nuclear medicine physician (WN) and a nuclear
physicist (RB). SUVmax was defined as the highest SUV per
voxel within one lymphomatous lesion. In this paper, SUVmax
is reported as the mean of SUVmax across all lesions of an
individual patient. SUVmax single highest was defined as the
highest SUVmax of all lesions within an individual patient.
Statistical analysis
Comparison between continuous, non-normally distribut-
ed variables was estimated by Wilcoxon rank-sum test.
Differences between two nominal variables were evaluat-
ed using Pearson’s chi-square or Fisher’s exact test (for
expected groups sizes ≤ 5). For exploratory survival anal-
ysis, the primary endpoints were overall survival (OS),
progression-free survival (PFS) and disease-specific sur-
vival (DSS). OS was defined as the time from diagnosis
until death (from any cause). PFS was defined as the time
from diagnosis until death or relapse or progression [12].
DSS was defined as the time from diagnosis until death
from DLBCL. Surviving patients were censored at the last
date of follow-up. Survival curves were estimated accord-
ing to the Kaplan-Meier method. Cox regression was used
for univariate and multivariate survival analyses and
results were reported as hazard ratio (HR), 95% confi-
dence interval (CI) and p value based on statistical Wald
test. A two-tailed p value of less than 0.05 indicated sta-
tistical significance. All analyses were performed using R
version 3.4.1 and R-studio version 1.0.153 software.
Results
Patient characteristics
Characteristics of the entire cohort (61 patients) are
summarised in Table 1. A total of 21 patients (34%) had a
DLBCL harbouring a MYC rearrangement. MYC rearrange-
ment was observed in 11 patients (21.6%) primarily seen in
the UMCG (n = 51) and 10 patients (100%) referred from
affiliated hospitals (n = 10). MYC groups did not differ with
regard to baseline characteristics (Table 1) except for serum
LDH levels, which were higher in the MYC-positive group
(p = 0.036) than in cases without MYC rearrangement.
MYC status, necrosis and semiquantitative 18F-FDG
PET parameters
necrosisPET was observed in 15 patients (25%). The relation-
ships between MYC status and necrosisPET, necrosisHist and
semiquantitative 18F-FDG PET parameters are summarised
in Table 2. MYC+ cases did not differ from cases without
Table 2 Necrosis and
semiquantitative 18F-FDG PET
parameters according to MYC
status
MYC status
Total (n = 61) MYC− (n = 40) MYC+ (n = 21) p value
No. % No. % No. %
necrosisPET
Absent 46 75.4 30 75.0 16 76.2 1.0c
Present 15 24.6 10 25.0 5 23.8
necrosisHist
Absent 42 68.9 28 70.0 14 66.7 0.52c
Present 16 26.2 11 27.5 5 23.8
Not available 3 4.9 1 2.5 2 9.5
SUVmax
Median (range) 13.0 (3.0–38.4) 13.1 (3.0–33.9) 10.4 (5.8–38.4) 0.43b
SUVmax single highest
Median (range) 18.8 (3.8–45.8) 19.7 (3.8–39.0) 14.2 (5.8–45.8) 0.49b
MATV
Median (range) 154.7 (1–3774) 156.0 (1–2800) 154.7 (7–3774) 0.68b
TLG
Median (range) 1387.4 (3–29,462) 1632.8 (3–29,462) 1147.1 (47–20,065) 0.62b
bWilcoxon rank-sum test
c Fisher’s exact test for count data
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MYC rearrangement with regard to necrosisPET (p = 1.0) or
necrosisHist (p = 0.52).
When the semiquantitative parameters SUVmax, SUVmax
single highest, MATV and TLG were studied, no difference
between MYC groups was observed. There was no relation
between the presence of necrosisPET and necrosisHist (p = 0.1;
Supplementary Figure 1).
NecrosisPET and tumour volume
In 14 of 15 necrosisPET cases, necrosis was observed in
the largest lesion. In comparison, the largest individual
lesion of cases without necrosisPET had a significantly
lower MATV (p = 0.0006) and SUVmax (p = 0.02), irre-
spective of MYC status (Supplementary Figure 2). Bulky
disease was observed in 24 patients (39%). Bulky disease
was significantly correlated with necrosisPET (p = 0.005),
but not with MYC status (p = 0.9) or necrosisHist (p = 0.8).
Extranodal growth of lesions was not significantly corre-
lated with the presence of necrosisPET (p = 0.26).
Survival analysis
The median follow-up was 34 months. At 5 years, OS was
67% (95% CI 54–83%), PFS was 65% (95% CI 53–81%) and
DSS was 81% (95% CI 70–93%) for the entire cohort. Of the
seven deaths unrelated to lymphoma, two were caused by
metastatic adenocarcinoma, two were due to cardiac failure,
one was due to acute on chronic renal failure and there were
two cases of sudden deaths in patients in complete remission
of DLBCL.
Results of the univariate Cox regression analysis (HR, 95%
CI and p value) are shown in Table 3. The univariate analysis
for OS identifiedMYC, NCCN-IPI and SUVmax single highest
as associated factors. In univariate analysis for PFS, only
NCCN-IPI was associated with outcome. In the univariate
analysis for DSS MYC, NCCN-IPI, SUVmax single highest
and necrosisPET were associated. Both SUVmax and SUVmax
single highest showed negative beta-coefficients throughout
the univariate survival analysis.
For multivariate analysis, the parametersMYC, NCCN-IPI,
necrosisPET and SUVmax single highest were used due to their
Table 3 Univariate analysis of patient characteristics and semiquantitative 18F-FDG PET parameters on overall survival, progression-free survival and
disease-specific survival
Hazard ratio OS 95% CI p value
(Wald test)
Hazard ratio PFS 95% CI p value
(Wald test)
Hazard ratio DSS 95% CI p value
(Wald test)
MYC
MYC-negative Reference Reference Reference
MYC-positive 2.9 1.1–7.4 0.025* 2.3 0.97–5.7 0.058 6.3 1.7–24 0.007**
NCCN-IPI
0–3 Reference Reference Reference
4–8 3.0 1.0–8.3 0.04* 3.6 1.3–10 0.013* 10.7 1.4–84 0.024*
necrosisPET
Absent Reference Reference Reference
Present 1.7 0.6–4.5 0.3 1.8 0.7–4.6 0.2 3.9 1.2–13 0.025*
SUVmax
< Median Reference Reference Reference
≥Median 0.4 0.1–1.1 0.08 0.4 0.2–1.1 0.08 0.2 0.05–1.1 0.06
SUVmax single highest
< Median Reference Reference Reference
≥Median 0.3 0.09–0.9 0.026* 0.4 0.2–1.1 0.07 0.1 0.01–0.8 0.028*
MATV
< Median Reference Reference Reference
≥Median 1.1 0.4–2.7 0.9 1.3 0.5–3.1 0.59 2.8 0.7–10.6 0.14
Single lesion MATV†
< Median Reference Reference Reference
≥Median 1.2 0.5–3.2 0.69 1.5 0.6–3.7 0.39 2.5 0.6–9.6 0.19
TLG
< Median Reference Reference Reference
≥Median 0.6 0.2–1.6 0.31 0.8 0.3–1.9 0.57 1.1 0.3–3.8 0.84
†Volume of the single largest/necrotic lesion; * = significance level of p < 0.05; ** = significance level of p < 0.01
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prognostic impact on lymphoma-related deaths in univariate
analysis (Table 4). NecrosisPET did not contribute to the prog-
nostic model for OS and PFS. However, for DSS, necrosisPET
had a large adverse prognostic impact and proved to be
independent (HR = 13.9; 95% CI 3.0–65; p = 0.001). The
Kaplan-Meier analysis for DSS showed no events during the
5-year follow-up period for patients who neither had MYC
rearrangements nor had necrosisPET (n = 30) (Fig. 3).
Table 4 Multivariate analysis of
patient characteristics on overall
survival, progression-free surviv-
al and disease-specific survival






MYC-positive 3.1 1.1–8.7 0.029*
NCCN-IPI
0–3 Reference
4–8 2.4 0.8–6.9 0.116
necrosisPET
Absent Reference
Present 2.6 0.9–7.7 0.079
SUVmax single highest
< Median Reference
≥Median 0.3 0.1–0.9 0.027*






MYC-positive 2.4 0.9–6.3 0.07
NCCN-IPI
0–3 Reference
4–8 3.2 1.1–9.0 0.028*
necrosisPET
Absent Reference
Present 2.6 1.0–7.0 0.06
SUVmax single highest
< Median Reference
≥Median 0.4 0.2–1.1 0.08






MYC-positive 14.6 2.6–82 0.002**
NCCN-IPI
0–3 Reference
4–8 6.5 0.6–66 0.113
necrosisPET
Absent Reference
Present 13.3 2.8–63 0.001**
SUVmax single highest
< Median Reference
≥Median 0.12 0.01–1.2 0.075
* = significance level of p < 0.05; ** = significance level of p < 0.01
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Discussion
Based on the current investigation, there is no association ofMYC
rearrangements with the presence of tumour necrosis assessed by
18F-FDG PET or the semiquantitative 18F-FDG PET parameters
SUVmax, SUVmax single highest, MATVand TLG. We therefore
rejected the hypothesis that metabolic changes induced by MYC
rearrangements might increase the incidence of necrosisPET or
alter the profile of semiquantitative parameters in DLBCL.
NecrosisPET was significantly associated with the MATVof the
single largest tumour lesion. The SUVmax of the single largest
necrosisPET lesion was significantly higher compared with the
lesions without necrosisPET. Both of these observations support
the notion of larger, more metabolically active tumours being
more susceptible to necrosis, irrespective ofMYC status.
Our analyses demonstrate that necrosisPET had a significant
impact on DSS, thereby substantiating previous findings
about the prognostic value of this visual marker [15]. The
presented data show that the presence ofMYC rearrangement,
in itself a powerful predictive factor, is not related to
necrosisPET. This allows for integration of MYC status and
necrosisPET into a prognostic model for DLBCL. When com-
bined withMYC, NCCN-IPI and SUVmax single highest in the
multivariate analysis, necrosisPET had the highest significance
in predicting death due to lymphoma and a higher prognostic
impact than NCCN-IPI, the currently most accurate prognos-
tic index for DLBCL [22]. Thus, our results support the po-
tential additive value of necrosisPETas an important biomarker
for risk stratification in the clinical setting [14, 15].
The lack of a relationship between MYC rearrangements
and semiquantitative 18F-FDG PET metrics might have sev-
eral causes. First, proliferation in DLBCL could be indepen-
dent ofMYC rearrangement. This would only partially explain
the lack of relationship, since the median proliferation index
Fig. 3 Kaplan-Meier curve showing disease-specific survival according to combined analysis withMYC rearrangement status and necrosisPET (log-rank
test, p = 0.00022). No events were observed in patients without MYC rearrangement and who had no necrosisPET
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(Ki-67 staining) ofMYC+DLBCL is universally high (> 90%)
in contrast to the much broader range observed in MYC−
DLBCL [29]. Second, overexpression of MYC via other
mechanisms such as epigenetic pathways might explain in-
creased glucose uptake in MYC FISH–negative DLBCL.
This is supported by studies showing high MYC protein ex-
pression in 19–40% of DLBCL cases [30–32]. Cottereau et al
previously reported a lack of relation between MYC protein
expression and 18F-FDG PET parameters in DLBCL [19].
However, FISH analysis, which is considered the gold stan-
dard examination for MYC rearrangements [33–35], was not
performed. Third, highmetabolic activity might be induced by
alternative changes in metabolic drivers, such as mutations in
PTEN (observed in approximately 15% of DLBCL) that lead
to activation of the P13K/AKT/mTOR pathway [29, 36–38].
Intriguingly, the univariate survival analysis indicated a
protective effect for cases with SUVmax and SUVmax single
highest measurements above the median. Studies on the prog-
nostic impact of these variables are conflicting [20, 39–41].
Gallicchio et al published results similar to ours, alluding to
lymphomas with high metabolic activity being more respon-
sive to chemotherapy [20]. In light of conflicting data on the
prognostic value of semiquantitative 18F-FDG PET parame-
ters [19–21, 42, 43], our results underline the need for larger,
prospective studies with external validation cohorts [42].
This study has several limitations. First there is a referral bias
with a high incidence of MYC+ cases (34%) in our dataset. The
enrichment in our study can largely be explained by the fact that,
as a reference centre, aggressive and MYC+ DLBCL cases
(including suspected cases of Burkitt lymphoma which subse-
quently prove to be MYC+ DLBCL) are referred to our site.
Second, the total number of cases with necrosisPET is small,
which increases the risk of a sampling error. Nevertheless, the
incidence of necrosisPET in our study is in line with previous
studies [13–15]. Furthermore, patients were included irrespective
of their comorbidities. Factors like differences in treatment regi-
men and non-cancer-related deaths might thus have a large im-
pact on the statistical analysis. This is supported by the difference
between DSS and OS. Despite its limitations, the prognostic
potential of MYC status and NCCN-IPI was reproduced in this
dataset, making it a representative set of DLBCL cases. Larger
prospective studies are warranted to validate the prognostic value
of necrosisPET.
Conclusion
In this comprehensive analysis of MYC rearranged DLBCL,
we showed that a fundamental pathological change such as
MYC rearrangement, which by itself has a significant impact
on prognosis, has no influence on the presence of necrosisPET
or semiquantitative 18F-FDG PET metrics. An explorative
survival analysis suggests that the presence of necrosis
determined by visual assessment of 18F-FDG PET scans is
an independent predictor of disease-specific survival in pa-
tients with DLBCL, regardless of MYC status.
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